Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance
Abstract Recent breakthroughs in targeted therapy and immunotherapy have revolutionized the treatment of lung cancer, the leading cause of cancer-related deaths in the United States and worldwide. Here we provide an overview of recent progress in immune checkpoint blockade therapy for treatment of n...
Main Authors: | Xingxiang Pu, Lin Wu, Dan Su, Weimin Mao, Bingliang Fang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-11-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4990-5 |
Similar Items
-
Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
by: Ya Xu, et al.
Published: (2020-10-01) -
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
by: Charissa A. C. Jessurun, et al.
Published: (2017-09-01) -
Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer
by: Jin-Chul Kim, et al.
Published: (2021-05-01) -
Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
by: Miren Zuazo, et al.
Published: (2020-11-01) -
Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC
by: Jialin Qu, et al.
Published: (2020-07-01)